The aim of this trial is to find out if there are any differences in the profiles of acute
and late adverse effects among men with low and intermediate risk prostate cancer treated
either with low dose-rate brachytherapy or hypofractionated external radiotherapy
(CyberKnife). Also the prostate specific antigen (PSA) responses and cost utility of each
treatment will be analysed.